Expanding the Chemical Space of Aryloxy-naphthoquinones as Potential Anti-chagasic Agents: Synthesis and Trypanosomicidal Activity

Expanding the Chemical Space of Aryloxy-naphthoquinones as Potential Anti-chagasic Agents: Synthesis and Trypanosomicidal Activity | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Expanding the Chemical Space of Aryloxy-naphthoquinones as Potential Anti-chagasic Agents: Synthesis and Trypanosomicidal Activity Nohemí A. Becerra, Christian Espinosa-Bustos, Karina Vázquez, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-756093/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 5 You are reading this latest preprint version Abstract In continuation our effort to research the chemical space of aryloxy-naphthoquinones as potential anti-Chagas agents, we synthesized nine derivatives and these compounds were evaluated in vitro against the epimastigote and trypomastigote forms of Mexican strains of Trypanosoma cruzi ( T. cruzi ). Most of these derivatives are highly active against epimastigote forms (IC 50 < 1.0 µM) compared to the reference drug benznidazole (Bzn). Then these were evaluated on trypomastigotes, which is showing better potency results than Bzn for compounds 3b and 3g . In addition, the cytotoxicity of these compounds was determined on the murine macrophage cell line J774. 3b and 3i were the most selective compounds against NINOA trypomastigote and INC-5 epimastigote forms, respectively. Further these compounds also have good oral bioavailability according to theoretical predictions. Finally, we were able to determine optimal substitution patterns using pharmacophoric models. All these results are provided very useful structural information to continue our designing of naphthoquinone derivatives against T. cruzi . Medicinal Chemistry Trypanosoma cruzi trypomastigote epimastigote aryloxy-naphthoquinones pharmacophoric analysis ADME properties Figures Figure 1 Figure 2 Figure 3 Introduction Chagas disease or American trypanosomiasis is one of the 20 “Neglected Tropical Diseases” (NTD) (WHO, 2020). The disease is caused by Trypanosoma cruzi ( T. cruzi ), a protozoan parasite endemic in Latin America. It affects approximately 7 million people and causes more than 10 000 deaths a year [ 1 ]. There are two drugs approved for the treatment of this disease, benznidazole (Bzn) and nifurtimox (Nfx) [ 2 ]. Both are effective in the early stages of the disease (acute stage), but their efficacy is limited in advanced stages (chronic stage). These drugs also present serious adverse effects and require long-term therapy leading to treatment suspension [ 3 , 4 ]. Considering the above and the fact the pharmaceutical industry does not invest in research for NTDs, it is great importance to find new alternatives for the treatment of trypanosomiasis. For this reason, many academic research groups are searching for new trypanosomicidal therapeutic alternatives through the design and synthesis of small molecules [ 5 , 6 ]. Compounds derived from a naphthoquinone scaffold appear to be an interesting alternative for the Chagas disease pharmacotherapy. Lapachol I and α-lapachone II (Fig. 1 ) are important naphthoquinone derivatives in nature with trypanosomicidal activity [ 7 , 8 ]. Considering this background, a library of 2-aryloxy-1,4-naphthoquinone compounds were synthesized by Bolognesi et al. 2-phenoxy-1,4-naphthoquinone III (Fig. 1 ) was the most prominent derivative in this series, with an IC 50 of 1.70 µM against T. cruzi amastigotes [ 9 ]. In recent years, our research group has focused on the search for new anti- T. cruzi agents containing the structure of the aryloxy-quinone scaffold. Our first approach was through the synthesis of aryloxy-indolequinone derivatives and their evaluation against T. cruzi epimastigotes culture. Of these, 6-phenoxyindolequinone derivative IV (Fig. 1 ) showed excellent inhibitory activity in the nanomolar range against Y strain epimastigote (IC 50 = 20 nM) [ 10 ]. In a subsequent article, our group reported the synthesis and trypanosomicidal activity of 2-aryloxy-naphthoquinones, 7-aryloxyquinolinquinones and 6-aryloxy-furonaphthoquinones derivatives [ 11 ]. In this work compound 2-(3-nitrophenyloxy)-naphthoquinone V (Fig. 1 ) showed an IC 50 = 20 nM and a selectivity index (SI) of 625 against J774 murine macrophage cells, which showed low toxicity against non-neoplastic cells. In our last report on aryloxy-naphthoquinones with trypanosomicidal activity, we obtained good results against epimastigote cultures with an IC 50 = 230 nM for 2-(4-methyl-3-nitrophenoxy)-naphthoquinone VI (Fig. 1 ) [ 12 ]. From these results, we observed the presence of an aryloxy group attached to the naphthoquinone core is important for anti- T. cruzi activity. Furthermore, we have noticed the addition of a nitro or a methyl group on the aryloxy moiety gives rise to compounds with equal or better trypanosomicidal activity. It remarked that Nfx and Bzn, drugs have been used in the chemotherapy of Chagas disease, have a nitro group in their structure. Interestingly, in 2017 the FDA has approved Bzn as pharmacological treatment for the Chagas disease [ 13 ]. Therefore, considering the aforementioned, in this work, we carried out the synthesis of new naphthoquinones (Fig. 1 ), which was functionalized according to four criteria, to evaluate the effect of these modifications on the trypanosomicidal effect on epimastigote and tripomastigote forms from Mexican strains of T. cruzi . These modifications were: (a) the substitution of the hydrogen atom on C-3 by bromine or chlorine because it has been reported that this change modulates the trypanosomicidal activity on Tulahuén, NINOA, INC-5 and Y strains [ 14 ]. In the aryloxy moiety: (b) the substitutions of a nitro group in the aryloxy moiety at meta or para position; (c) as shown in VI , a methyl group at para position and meta position; (d) a substitution at para position by chlorine atom. With these new derivatives, our group expanded the library of compounds with trypanosomicidal activity and contributed to the chemical space of naphthoquinones with anti-Chagasic activity. Experimental Section General Melting points were determined on a Kofler Thermogerate apparatus and were uncorrected. IR spectra were recorded on a JASCO FT/IR-400 spectrophotometer. NMR spectra were recorded, unless otherwise specified, on a Bruker AM-400 instrument using deuterochloroform (CDCl 3 ) or deuterodimethylsulfoxide (DMSO-δ) solutions containing tetramethylsilane as an internal standard. Samples were analysed using an Advion (Itaca, NY, USA) Expression-L mass spectrometer equipped with an electrospray ionization source (ESI). Sample were directly injected (5 µL) using LC-grade methanol as mobile phase. Mass spectrometry analysis was carried out using the following settings: ESI (-) voltage of 2.5 kV, nebulizer gas (N 2 ) flow: 3.0 L min-1, drying gas flow: 10 L min-1, desolvation line temperature 200°C and heat block temperature 250°C. Analytes were evaluated in Full Scan mode (m/z) 100–1500. Data was acquired by means of Advion Mass Express and processed applying Data Express Software. Thin layer chromatography (TLC) was performed using Merck GF-254 type 60 silica gel. Column chromatography was carried out using Merck type 9385 silica gel. The purity of the compounds was determined by TLC. All the spectra of aryloxy-quinones synthesized are shown in the Supporting information. General procedure for the synthesis of aryloxy-naphthoquinones. In a reaction flask, the suitable phenol (1.1 mmol) and K 2 CO 3 (2 mmol) were suspended in DMF (5 mL). The mixture was stirred for 10 min, and then, the corresponding naphthoquinone (1 mmol) was added. Later, the reaction mixture was stirred for 2–3 h at room temperature. The solvent was then removed under vacuum, and the solid residue was purified by column chromatography on silica gel and using dichloromethane as the mobile phase. 2-(4-Methyl-3-nitrophenoxy)naphthalene-1,4-dione 3a. Yellow solid, yield 63 %, mp 163–165°C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.21–8.15 (m, 1H), 8.10–8.03 (m, 1H), 7.81 (d, J = 2.5 Hz, 1H), 7.79–7.75 (m, 2H), 7.46 (d, J = 8.4 Hz, 1H), 7.32 (dd, J = 8.4, 2.5 Hz, 1H), 6.01 (s, 1H), 2.64 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 184.48, 179.34, 159.48, 151.07, 149.73, 134.67, 134.63, 133.81, 131.99, 131.82, 130.96, 126.90, 126.38, 125.71, 117.51, 114.42, 20.12. MS (ESI) for (C 17 H 11 NO 5 [M-]): 309.3. Found 309.0. 2-Chloro-3-(4-methyl-3-nitrophenoxy)naphthalene-1,4-dione 3b. Yellow solid, yield 23 %, mp 201–203°C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.22 (d, J = 7.0 Hz, 1H), 8.05 (d, J = 6.8 Hz, 1H), 7.85–7.74 (m, 2H), 7.61 (d, J = 1.6 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.24–7.17 (m, 1H), 2.58 (s, 3H). 13 C NMR (101 MHz, CDCl 3 ) δ 178.02, 177.62, 154.49, 152.74, 149.27, 134.85, 134.67, 134.47, 134.00, 131.16, 130.43, 129.37, 127.58, 127.31, 121.66, 112.82, 20.02. MS (ESI) for (C 17 H 10 ClNO 5 [M-]): 343.0. Found 343.0. 2-Bromo-3-(4-methyl-3-nitrophenoxy)naphthalene-1,4-dione 3c. Yellow solid, yield 24 %, mp 188–190°C. 1 H NMR (400 MHz, CDCl3) δ 8.16–8.08 (m, 1H), 7.95 (dd, J = 7.2, 1.7 Hz, 1H), 7.76–7.64 (m, 2H), 7.52 (d, J = 2.6 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.13 (dd, J = 8.4, 2.6 Hz, 1H), 2.49 (s, 3H). 13 C NMR (101 MHz, CDCl 3 ) δ 178.07, 177.09, 155.21, 154.37, 149.28, 134.81, 134.59, 134.01, 131.06, 130.44, 129.33, 128.61, 127.84, 127.37, 121.64, 112.81, 20.02. MS (ESI) for (C 17 H 10 BrNO 5 [M-]): 386.9. Found 387.0 2-(4-Chloro-3-nitrophenoxy)naphthalene-1,4-dione 3d. Yellow solid, yield 54 %, mp 164–165°C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.18–8.14 (m, 1H), 8.09–8.05 (m, 1H), 7.83–7.74 (m, 2H), 7.72 (d, J = 2.8 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.35 (dd, J = 8.8, 2.8 Hz, 1H), 6.11 (s, 1H). 13 C NMR (101 MHz, CDCl 3 ) δ 184.25, 179.06, 158.73, 151.80, 148.51, 134.80, 133.97, 133.66, 131.75, 130.88, 126.95, 126.48, 125.68, 124.71, 118.27, 115.61. MS (ESI) for (C 16 H 8 ClNO 5 [M-]): 329.0. Found 328.9. 2-Chloro-3-(4-chloro-3-nitrophenoxy)naphthalene-1,4-dione 3e . Yellow solid, yield 43 %, mp 199–201°C. 1 H NMR (400 MHz, DMSO) δ 8.14 (dd, J = 7.3, 1.4 Hz, 1H), 8.09 (d, J = 2.9 Hz, 1H), 8.02 (dd, J = 7.1, 1.7 Hz, 1H), 7.99–7.92 (m, 2H), 7.80 (d, J = 8.9 Hz, 1H), 7.67 (dd, J = 8.9, 3.0 Hz, 1H). 13 C NMR (101 MHz, DMSO) δ 178.47, 177.95, 155.51, 151.95, 148.86, 135.15, 135.01, 134.85, 133.13, 131.94, 131.10, 127.14, 127.00, 122.24, 119.30, 113.43. MS (ESI) for (C 16 H 7 Cl 2 NO 5 [M-]): 362.9. Found 363.0. 2-Bromo-3-(4-chloro-3-nitrophenoxy)naphthalene-1,4-dione 3f. Yellow solid, yield 67 %, mp 196–198°C. 1 H NMR (400 MHz, DMSO) δ 8.18–8.11 (m, 1H), 8.08 (d, J = 2.9 Hz, 1H), 8.06–7.98 (m, 1H), 7.97–7.87 (m, 2H), 7.79 (d, J = 8.9 Hz, 1H), 7.66 (dd, J = 8.9, 2.9 Hz, 1H). 13 C NMR (101 MHz, DMSO) δ 178.73, 177.47, 155.39, 154.40, 148.90, 135.08, 134.93, 133.11, 131.83, 131.13, 129.70, 127.38, 127.07, 122.19, 119.17, 113.37. MS (ESI) for (C 16 H 7 BrClNO 5 [M-]): 408.6. Found 409.0. 2-Chloro-3-(4-nitrophenoxy)naphthalene-1,4-dione 3g. Yellow solid, yield 61 %, mp 169–170°C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.40–8.31 (m, 3H), 8.21–8.15 (m, 1H), 8.00–7.86 (m, 2H), 7.28–7.13 (m, 2H). 13 C NMR (101 MHz, CDCl 3 ) δ 177.86, 177.28, 160.65, 152.42, 143.89, 134.98, 134.81, 131.14, 130.33, 127.68, 127.38, 126.04, 116.77. MS (ESI) for (C 16 H 8 ClNO 5 [M-]): 329.0. Found 328.9. 2-Chloro-3-(3-methyl-4-nitrophenoxy)naphthalene-1,4-dione 3h. Yellow solid, yield 37 %, mp 170–171°C. 1 H NMR (400 MHz, DMSO) δ 8.19–8.10 (m, 1H), 8.06 (d, J = 9.0 Hz, 1H), 8.01 (dd, J = 7.1, 1.5 Hz, 1H), 7.98–7.87 (m, 2H), 7.38 (d, J = 2.5 Hz, 1H), 7.31 (dd, J = 9.0, 2.7 Hz, 1H), 2.51 (s, 2H). 13 C NMR (101 MHz, DMSO) δ 178.48, 177.94, 159.47, 152.08, 144.56, 136.99, 135.16, 135.02, 134.99, 131.98, 131.06, 127.69, 127.18, 127.04, 119.70, 115.16, 20.46. MS (ESI) for (C 17 H 10 ClNO 5 [M-]): 343.0. Found 343.0. 2-Bromo-3-(3-methyl-4-nitrophenoxy)naphthalene-1,4-dione 3i. Yellow solid, yield 32 %, mp 174–176°C. 1 H NMR (400 MHz, CDCl3) δ 8.27–8.11 (m, 1H), 8.11–7.95 (m, 2H), 7.85–7.71 (m, 2H), 6.94–6.87 (m, 2H), 2.59 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 178.00, 176.87, 158.86, 154.99, 144.74, 137.29, 134.89, 134.69, 131.08, 130.38, 129.07, 127.92, 127.49, 127.46, 119.90, 114.41, 21.27. MS (ESI) for (C 17 H 10 BrNO 5 [M-]): 386.9. Found 387.0. Trypanosomicidal effect T. cruzi NINOA and INC-5 strain epimastigotes were grown at 28°C in an axenic medium (BHI), as previously described [ 22 ], and complemented with 5 % foetal bovine serum. Epimastigotes from a 10-day-old culture (stationary phase) were inoculated into 50 mL of fresh culture medium to reach an initial concentration of 1 × 10 6 . Cell growth was monitored by measuring culture absorbance of the culture at 600 nm in an ELISA Epoch reader (Epoch 2 Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) every day. Before inoculation, the media was supplemented with a given amount of the drug from a stock solution in DMSO (25 mM). The final DMSO concentration in the culture medium never exceeded 0.4 % and the control was run in the presence of 0.4 % DMSO and in the absence of drugs. The percentage of growth inhibition (% GI) and half-maximal inhibitory concentration values (IC 50 ), and parasite growth were followed in the absence (control), and in the presence, of a range of concentrations of the corresponding drug. On day 5, the absorbance of the culture was measured and related to the control. The IC 50 value was determined as the concentration of drug needed to reduce the absorbance ratio by 50 %. The experiments of each compound were carried out in triplicate; Bzn was used as a reference compound. Ex vivo evaluation of INC-5 and NINOA strain trypomastigotes CD1 mice, 6 to 8 weeks old, were peritoneally infected with bloodstream trypomastigotes of the INC-5 and NINOA strains, respectively. After 4 to 6 weeks, at the maximum peak of parasitaemia, the parasitized blood was obtained by cardiac puncture using sodium heparin as an anticoagulant. Blood was adjusted to 1 x 10 6 trypomastigotes/mL. In a 96-well plate, 90 µl of infected blood and 10 µl of 1,4-naphthoquinone derivatives or reference drug dilutions were deposited for a final volume of 100 µl per well. Each evaluation was carried out in triplicate. The compounds with the best IC 50 in the epimastigotes of each strain were evaluated in trypomastigotes of both strains at 20 µM, 10 µM and 5 µM. The reference drug benznidazole was used as a positive lysis control and wells with untreated blood trypomastigotes were used as a negative lysis control; the microplates were incubated at 4°C for 24 h. Subsequently, mobile trypomastigotes were quantified using the Brener-Pizzi method, for this, 5 µL of blood was deposited between a slide and a 13 × 13 coverslip. The trypomastigotes were counted in 15 microscope fields in an optical microscope with 40x magnification. The percentage of lysis of each treatment was calculated by comparing the viable trypomastigotes with the negative control [ 16 ]. The LC 50 was determined by linear regression. The experiments were carried out in accordance with the recommendations and approval of the local Ethics and Research Committee (Approval number: ENCB / CEI / 078/2020). Cytotoxicity assays A 96-well plate was seeded with 50 000 cells/well with RPMI medium and 2 % foetal bovine serum and incubated for 24 h at 37°C. The compound from stock was dissolved in DMSO for subsequent serial dilutions with PBS until a concentration in the plate that did not exceed 1 % of DMSO was reached. After 24 h, the culture medium was removed from the plate and fresh culture medium was added together with the compounds reaching a final volume of 100 µl per well. The plate was then incubated for 24 h at 37°C in 5 % CO 2 where the following controls were added: cells with the medium as a positive control; cells without culture medium as a negative control; and last, the reference drug, Bzn at a concentration of 20 µM. After 24 h of incubation, the cell morphology was observed with a microscope and the MTT viability assay was performed. The culture medium was removed and the MTT solution was prepared and later added to the cells; it was incubated for 1 h and the absorbance was read at 570 nm. The following formula was used to obtain the percentage: % cytotoxicity = (100-(mean number of cells with treatment/cells without treatment) *100) [ 23 ]. Pharmacophore A flexible alignment strategy was used, consisting of the overlap of 3D structures, and minimizing the relative distances between equivalent atoms, including the flexibility for all freedom degrees for all rotatable dihedral bonds. Polar-Charged-Hydrophobic (PCH) of the MOE program was used and evaluated over a centroid position (an averaged position of all atoms relates to the feature). Pharmacophoric features in this scheme are annotated as Aro (aromatic), hydrophobic (Hyd), acceptor hydrogen bonding (Acc), and capacity to bound to metallic centres (ML). Afterward, databases were spotted in groups of high and low growth inhibition of parasites in epimastigotes or trypomastigotes of INC-5, NINOA, respectively. For each group, a pharmacophore was built, and all features present in a minimum of 60 % of molecules were retained. Finally, all pharmacophores were compared. Results And Discussion Chemistry We synthesized new aryloxy-naphthoquinones by nucleophilic substitution reaction of phenols with halo or dihaloquinones in a basic medium at room temperature (Scheme 1 ) [ 12 , 15 , 11 ]. These aryloxy-naphthoquinones were obtained from low to moderate yields (23–67%). The chemical structures of the compounds 3a-i were established based on their spectral properties (IR, 1 H-NMR, 13 C-NMR and MS). The chemical structures and the yield for the synthesis of 3a-i are shown in the Table 1 . Table 1 Yields for synthesis of aryloxy-naphthoquinone derivatives Compound Structure Yield (%) 3a 63 3b 23 3c 24 3d 54 3e 43 3f 67 3g 61 3h 37 3i 32 Biology Trypanosomicidal effect against on the epimastigote form First, a screening assay was performed on the INC-5 and NINOA strains at a fixed concentration of 10 µM to determine the trypanosomicidal effect against epimastigote cultures. The results indicated that all compounds had a percentage of growth inhibition (% GI) in both strains greater than 70%. Considering these results, a dose-dependent assay was carried out using different concentrations (5 µM, 2.5 µM, 1.25 µM, 0.625 µM to determine the half-maximal inhibitory concentration (IC 50 ) in each strain (Table 2 ). All the naphthoquinone derivatives showed greater potency than the reference drug Bzn on the INC-5 and NINOA epimastigotes strains. Interestingly, compounds 3i and 3c were 1000 and 100-fold more potent than Bzn against the INC-5 strain, respectively. From the chemical point of view, the most active compounds in both strains were 3i (IC 50 = 40 nM on INC-5) and 3f (IC 50 = 1.14 µM on INC-5). These compounds present a bromine atom at 3-position on the naphthoquinone scaffold. In general, in the INC-5 strain, compounds that have a halogen at 3-position, had greater potency than those did not present a substitution in this position ( 3a and 3d ). The same observation was noticed in the NINOA strain except for compound 3d , which presented a potency comparable to the derivatives that have halogens at 3-position. On the other hand, the position of the nitro, chloro, or methyl group on the aryloxy moiety does not seem to significantly affect the activity in either strain. However, the halogen attached at 3-position on the naphthoquinone core seems to influence the potency over epimastigotes, since the molecules with a bromine atom were more potent than those with a chlorine atom, and those without substitution in this position are the least active. Therefore, the order of activity follows the pattern: Br > Cl > H. Table 2 Effect of 3a-i and Bzn on culture growth of epimastigote and trypomastigote forms of T. cruzi Compound Epimastigote form Trypomastigote form INC-5 IC 50 (µM) a NINOA IC 50 (µM) INC-5 LC 50 (µM) NINOA LC 50 (µM) 3a 0.73 ± 0.04 4.86 ± 0.07 NT b NT 3b 0.51 ± 0.02 3.06 ± 0.05 NT 9.38 3c 0.41 ± 0.01 1.70 ± 0.42 24.74 20.35 3d 1.63 ± 0.02 2.26 ± 0.07 NT NT 3e 0.66 ± 0.01 2.15 ± 0.83 NT NT 3f 0.88 ± 0.03 1.14 ± 0.03 24.76 20.01 3g 0.64 ± 0.02 1.41 ± 0.05 39.11 9.75 3h 0.67 ± 0.02 1.45 ± 0.03 NT NT 3i 0.04 ± 0.02 1.84 ± 0.18 27.50 35.36 Bzn 42.3 ± 5.8 8.21 ± 1.8 46.67 40.67 a The results are means of three independent experiments b NT = not tested Trypanosomicidal effect against on the trypomastigote The half-maximal lytic concentration (LC 50 ) in the trypomastigote form of both strains was measured for the compounds showed the lowest IC 50 values. The best results were obtained in the NINOA strain with LC 50 values of 9.38 and 9.75 µM for compounds 3b and 3g , respectively (Table 2 ). These compounds were four-fold more active than Bzn (LC 50 = 40.67 µM). On the other hand, in the INC-5 strain, two compounds, 3c and 3g showed approximately two-fold greater potency than Bzn (LC 50 = 46.67 µM). However, it was not possible to establish a structure-activity relationship in trypomastigotes because the assayed compounds were limited in number It is remarkable that in NINOA, the most active compounds were those with a chlorine atom at 3-position on the naphthoquinone core. The important results are obtained from these strains. The trypomastigote is the infective flagellated form of the parasite in the blood. This form is responsible for the acute and chronic stages of Chagas disease in mammalian hosts [ 16 ]. Epimastigotes were used as a primary screening because their replication is extracellular, and they are easy to handle and maintain in the laboratory [ 17 ]. Cytotoxicity in murine macrophages The cytotoxicity of the most promising compounds 3b , 3c , 3f , 3g and 3i was determined on the murine macrophage J774 cell line (Table 3 ). In general, the five derivatives had greater selectivity for the epimastigote form of both strains, with 3i being the compound with the highest selectivity index (SI = 320). Moreover, it is important to point out the high selectivity of compound 3b against the NINOA strain in trypomastigotes. The SI for 3b was comparable with Bzn but with a better LC 50 on this strain than this reference drug. Table 3 Selective index (SI) values calculated for the most promising compounds Compound J774 IC 50 (µM) a INC-5(Epi) SI b NINOA (Epi) SI INC-5(Tryp) SI NINOA(Tryp) SI 3b 117 229 38.2 NT c 12.5 3c 9.4 23 5.5 0.4 0.5 3f 13.6 16 12.0 0.5 0.7 3g 11.9 19 8.4 0.3 1.2 3i 12.8 320 6.9 0.5 0.4 Bzn 352 8.3 42.8 7.5 8.7 a The results are means of three independent experiments b SI value = IC 50 values on J774 cells / IC 50 or LC 50 T. cruzi c NT = not tested Pharmacophoric elucidation Compounds were aligned by a flexible alignment technique. This technique overlaps 3D structures minimizing the relative distances between equivalent atoms (in each molecule), including flexibility that allows all degrees of freedom in the rotatable angles, covering all possible dihedral angles. The pharmacophoric model was built using the Polar-Charged-Hydrophobic (PCH) scheme in the MOE program [ 18 ]. The model was built with all features present in at least 60% of aligned molecules, resulting in the selection of the following features: Aromatic rings (Aro); Hydrophobic centre (Hyd); Hydrogen bond acceptor capacity (Acc); Metal ligation site (ML), and a combination of these. Some combinations could be defined (Acc&ML). Considering that there are more IC 50 values for the epimastigote form in both strains, a pharmacophoric model was carried out. Pharmacophoric models for INC-5 epimastigote T. cruzi growth inhibitors The molecules were classified according to their trypanosomicidal (INC-5 epimastigotes) high or low growth inhibition (Fig. 2 ); their differential features were also detected. The main difference observed between both groups was sites bound to metals ( meta -position, red spheres) non-favouring bioactivity. In this place, a nitro group at meta -position on aryloxy moiety favoured the desired bioactivity. This change affected the electronic density of the aromatic ring sustaining this group because of the high electronegativity of nitrogen and oxygen atoms of the nitro substituent. Pharmacophoric models of NINOA epimastigotes T. cruzi growth inhibitors The molecules were classified according to their trypanosomicidal (NINOA epimastigotes) high or low growth inhibition (Fig. 3 ); their differential features were also detected. In this case, bioactivity (NINOA T. cruzi epimastigotes growth inhibition) is favoured with the presence of acceptor groups of metallic atoms at para position on the phenoxy group (cyan spheres) and non-favoured when these features are placed at meta -position (red spheres). Physicochemical properties Drug-likeness properties such as the pharmacokinetic (ADME) and pharmacodynamic (e.g., toxicological) profiles are important during the process of discovery and development process of a drug. These properties are shown the optimization of a leading compound to a successful candidate for pre-clinical stages [ 19 ]. ADMET properties are important to determine some chemical descriptors such as the polar surface area (PSA) and the molecular weight (MW) of molecules, which are useful to determine the oral absorption of drugs. Small and hydrophilic molecules are undergoing rapid renal clearance, while large and hydrophobic compounds are undergoing extensive hepatic metabolism and poor absorption [ 20 ]. Therefore, finding a suitable hydrophilic-hydrophobic drug balance is a great challenge for medicinal chemists. Thus, to evaluate these properties and predict good oral bioavailability, two sets of rules, Lipinski and Veber, should be followed to make a good prediction [ 21 , 20 ]. Lipinski’s rule of five states that an orally bioavailable molecule should not violate the following criteria: ≤ 5 hydrogen bond donors (HBD); ≤ 10 hydrogen bond acceptors (HBA); a MW < 500, and a log P-value < 5. On the other hand, Veber et al. described the role of PSA and the number of rotatable bonds as criteria to estimate oral bioavailability. Veber’s rule states that the compound to be orally bioavailable, it should have either a PSA ≤ 140 Å and ≤ 10 rotatable bonds (NRB) or ≤ 12 HBD and HBA in total and ≤ 10 rotatable bonds. As shown in Table 4 , compounds 3a-i achieved the Drug-likeness criteria described by Lipinski and Veber; therefore, they are expected to have good oral bioavailability. Table 4 Molecular properties of compounds 3a-i Compound MW (Da) HBA HBD MiLogP TPSA (A 2 ) NRB Desirable value ≤ 500 ≤ 10 ≤ 5 ≤ 5 ≤ 140 ≤ 10 3a 309.28 6 0 3.69 89.20 3 3b 343.72 6 0 4.29 89.20 3 3c 388.17 6 0 4.42 89.20 3 3d 329.69 6 0 3.91 89.20 3 3e 364.14 6 0 4.52 89.20 3 3f 408.59 6 0 4.65 89.20 3 3g 329.69 6 0 3.91 89.20 3 3h 343.72 6 0 4.29 89.20 3 3i 388.17 6 0 4.42 89.20 3 MW: Molecular weight; HBA: Number of hydrogen bond acceptors; HBD: Number of hydrogen bond donors; MiLogP: Log P value predicted by Molinspiration ( www.https://www.molinspiration.com ); TPSA: Topological polar surface; NRB: number of rotatable bonds. Conclusions In this study, a set of nine aryloxy-naphthoquinones were synthesised and evaluated in vitro and ex vivo against the epimastigote and trypomastigote forms in two Mexican T. cruzi strains. The trypanosomicidal activity of these compounds against both forms and were better than the reference drug, benznidazole (Bzn). The most promising naphthoquinone derivative is compound 3b due to its highest trypanosomicidal activity against epimastigotes (INC-5 and NINOA strains) and trypomastigote (NINOA strain) and SI values. From the theoretical studies, important features from pharmacophoric models were identified to develop the more active naphthoquinone derivatives. Predictions about their ADME properties indicated that these aryloxy-naphthoquinones would have good bioavailability. Declarations Acknowledgements C.O.S. thanks to DIPOG project Nº 3913-406-81 and C. E.-B. gratefully acknowledges the financial support from FONDECYT (Research Grant No. 1180292). Conflict of interest The authors declare that there is no conflict of interest. References Organization WH. Available online: https://www.who.int/neglected_diseases/diseases/en/ . 2020 Zuma AA, de Souza W (2021) Chagas Disease Chemotherapy: What Do We Know So Far? Curr Pharm Des. doi: 10.2174/1381612827666210216152654 Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H (2011) Adverse Events After the Use of Benznidazole in Infants and Children With Chagas Disease. Pediatrics 127(1):e212–e218. doi: 10.1542/peds.2010-1172 Apt BW, Heitmann GI, Jercic LM, Jotre ML, Munoz CDVP, Noemi HI et al (2008) [Guidelines for chagas disease: Part IV. Chagas disease in immune compromised patients]. Rev Chilena Infectol 25(4):289–292. doi:/S0716-10182008000400008 Scarim CB, Chin CM (2019) Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances. Comb Chem High Throughput Screen 22(8):509–520. doi: 10.2174/1386207322666191010144111 Villalta F, Rachakonda G (2019) Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin Drug Discov 14(11):1161–1174. doi: 10.1080/17460441.2019.1652593 Boveris A, Docampo R, Turrens JF, Stoppani AO (1978) Effect of beta-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi . Bioch J 175(2):431–439. doi: 10.1042/bj1750431 Diogo EBT, Dias GG, Rodrigues BL, Guimarães TT, Valença WO, Camara CA et al (2013) Synthesis and anti- Trypanosoma cruzi activity of naphthoquinone-containing triazoles: electrochemical studies on the effects of the quinoidal moiety. Bioorg Med Chem 21(21):6337–6348. doi: 10.1016/j.bmc.2013.08.055 Bolognesi ML, Lizzi F, Perozzo R, Brun R, Cavalli A (2008) Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity. Bioorg Med Chem Lett 18(7):2272–2276. doi: 10.1016/j.bmcl.2008.03.009 Tapia RA, Salas CO, Vázquez K, Espinosa-Bustos C, Soto-Delgado J, Varela J et al (2014) Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents. Bioorg Med Chem Lett 24(16):3919–3922. doi: https://doi.org/10.1016/j.bmcl.2014.06.044 Vázquez K, Espinosa-Bustos C, Soto-Delgado J, Tapia RA, Varela J, Birriel E et al (2015) New aryloxy-quinone derivatives as potential anti-Chagasic agents: synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis. RSC Adv 5(80):65153–65166. doi: 10.1039/C5RA10122K Espinosa-Bustos C, Vázquez K, Varela J, Cerecetto H, Paulino M, Segura R et al (2020) New aryloxy-quinone derivatives with promising activity on Trypanosoma cruzi . Arch Pharm 353(1):1900213. doi: https://doi.org/10.1002/ardp.201900213 Jarvis LM (2018) the year in new drugs: fda approvals hit a 20-year high in 2017, with cancer and rare-disease drugs dominating the list of new medicines. Chem Eng News 96(4):25–30 González A, Becerra N, Kashif M, González M, Cerecetto H, Aguilera E et al. In vitro and in silico evaluations of new aryloxy-1,4-naphthoquinones as anti- Trypanosoma cruzi agents. Med Chem Res. 2020;29(4):665 – 74. doi: 10.1007/s00044-020-02512-9 Tapia RA, Salas C, Morello A, Maya JD, Toro-Labbe A (2004) Synthesis of dihydronaphthofurandiones and dihydrofuroquinolinediones with trypanocidal activity and analysis of their stereoelectronic properties. Bioorg Med Chem 12(9):2451–2458. doi: 10.1016/j.bmc.2004.01.046 Chacón-Vargas KF, Nogueda-Torres B, Sánchez-Torres LE, Suarez-Contreras E, Villalobos-Rocha JC, Torres-Martinez Y et al. Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors. Molecules. 2017;22(2). doi: 10.3390/molecules22020220 Martin-Escolano R, Martin-Escolano J, Ballesteros-Garrido R, Cirauqui N, Abarca B, Rosales MJ et al (2020) Repositioning of leishmanicidal [1,2,3]Triazolo[1,5- a ]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition. Parasitol Res 119(9):2943–2954. doi: 10.1007/s00436-020-06779-0 MOE (2013) Molecular Operating Environment 08, Chemical Computing. Group, Inc., Montreal Meanwell NA (2011) Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 24(9):1420–1456. doi: 10.1021/tx200211v Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1–3):3–26. doi: 10.1016/s0169-409x(00)00129-0 Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615–2623. doi: 10.1021/jm020017n Alvarez G, Varela J, Marquez P, Gabay M, Arias Rivas CE, Cuchilla K et al (2014) Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity. J Med Chem 57(10):3984–3999. doi: 10.1021/jm500018m Faundez M, Pino L, Letelier P, Ortiz C, Lopez R, Seguel C et al (2005) Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi . Antimicrob Agents Chemother 49(1):126–130. doi: 10.1128/AAC.49.1.126-130.2005 Supplementary Files SupportinginformationMCR2021.docx floatimage1.png Scheme01.png Scheme 1 Synthesis of aryloxy-naphthoquinone derivatives. Reagents and conditions: a) K2CO3, DMF, rt, 2-3 h, 23-67%. Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Major Revision 06 Sep, 2021 Reviews received at journal 01 Aug, 2021 Reviewers invited by journal 01 Aug, 2021 Editor assigned by journal 28 Jul, 2021 First submitted to journal 26 Jul, 2021 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-756093","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":43158791,"identity":"774239a2-624d-435a-a798-fc23bf7e098c","order_by":0,"name":"Nohemí A. Becerra","email":"","orcid":"","institution":"Universidad Autónoma de Nuevo León: Universidad Autonoma de Nuevo Leon","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Nohemí","middleName":"A.","lastName":"Becerra","suffix":""},{"id":43158792,"identity":"d85e370f-f6c9-44b7-824b-24929f42c7b5","order_by":1,"name":"Christian Espinosa-Bustos","email":"","orcid":"","institution":"Pontifical Catholic University of Chile: Pontificia Universidad Catolica de Chile","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Christian","middleName":"","lastName":"Espinosa-Bustos","suffix":""},{"id":43158793,"identity":"eb457417-2617-4ac0-9986-0bf2782a5d46","order_by":2,"name":"Karina Vázquez","email":"","orcid":"","institution":"Universidad Autónoma de Nuevo León: Universidad Autonoma de Nuevo Leon","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Karina","middleName":"","lastName":"Vázquez","suffix":""},{"id":43158794,"identity":"96f347c2-76e7-4a12-85f4-86323d8780a0","order_by":3,"name":"Gildardo Rivera","email":"","orcid":"","institution":"Instituto Politécnico Nacional: Instituto Politecnico Nacional","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Gildardo","middleName":"","lastName":"Rivera","suffix":""},{"id":43158795,"identity":"00b91859-fee7-4833-ab09-4aba83762a68","order_by":4,"name":"Margot Paulino","email":"","orcid":"","institution":"Universidad de la República Uruguay: Universidad de la Republica Uruguay","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Margot","middleName":"","lastName":"Paulino","suffix":""},{"id":43158796,"identity":"28972088-d49d-4c11-bdc7-58357d792bb7","order_by":5,"name":"Jorge Cantero","email":"","orcid":"","institution":"Universidad de la República Uruguay: Universidad de la Republica Uruguay","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jorge","middleName":"","lastName":"Cantero","suffix":""},{"id":43158797,"identity":"b214a967-95dd-45bf-a657-3a1338e3c9c8","order_by":6,"name":"Benjamín Nogueda","email":"","orcid":"","institution":"Instituto Politécnico Nacional: Instituto Politecnico Nacional","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Benjamín","middleName":"","lastName":"Nogueda","suffix":""},{"id":43158798,"identity":"187edac8-a1bd-4733-9a7d-d7430f0d06fb","order_by":7,"name":"Fabiola Chacón-Vargas","email":"","orcid":"","institution":"Universidad Autonoma de Chihuahua","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Fabiola","middleName":"","lastName":"Chacón-Vargas","suffix":""},{"id":43158799,"identity":"9e870643-a696-4fce-a7a3-07cc04d2bc79","order_by":8,"name":"Uziel Castillo-Velazquez","email":"","orcid":"","institution":"Universidad Autónoma de Nuevo León: Universidad Autonoma de Nuevo Leon","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Uziel","middleName":"","lastName":"Castillo-Velazquez","suffix":""},{"id":43158800,"identity":"347ff630-72f0-43d1-b560-58988de2c102","order_by":9,"name":"Ana F. Elizondo Rodríguez","email":"","orcid":"","institution":"Universidad Autónoma de Nuevo León: Universidad Autonoma de Nuevo Leon","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ana","middleName":"F. Elizondo","lastName":"Rodríguez","suffix":""},{"id":43158801,"identity":"c334d57d-79ad-47b7-b11e-6011aaa70a6b","order_by":10,"name":"Sofía Toledo","email":"","orcid":"","institution":"Pontificia Universidad Católica de Chile: Pontificia Universidad Catolica de Chile","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sofía","middleName":"","lastName":"Toledo","suffix":""},{"id":43158802,"identity":"464be68e-5789-4a8f-a23a-df81ccba70a0","order_by":11,"name":"Adriana Moreno-Rodríguez","email":"","orcid":"","institution":"Universidad Autónoma Benito Juárez de Oaxaca: Universidad Autonoma Benito Juarez de Oaxaca","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Adriana","middleName":"","lastName":"Moreno-Rodríguez","suffix":""},{"id":43158803,"identity":"eb605c33-b15d-4a20-8cec-de6fb93e811e","order_by":12,"name":"Mario Aranda","email":"","orcid":"","institution":"Pontifical Catholic University of Chile: Pontificia Universidad Catolica de Chile","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Mario","middleName":"","lastName":"Aranda","suffix":""},{"id":43158804,"identity":"4412f93b-6203-4d00-8f15-3c73dbeab1f2","order_by":13,"name":"cristian osvaldo salas","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAnUlEQVRIiWNgGAWjYLCCBwwMcjAGkSCBgcEYxiBeS2ID0Vr429sffkioqUvfcPwA4weitEicOWMskXDscO6GMwnMEkRpMZDIYZBIYDuQu+EGAxtxDjOQSH/8I+FfXboBCVoSzCQS25gTiNcC9IuZRWLfYcOZZxKbifMLMMQe3/jwrU6e7/jhgx8+EKMFCTA2kKhhFIyCUTAKRgFOAACxIjJfeAOiuAAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0001-7620-2459","institution":"Pontificia Universidad Catolica de Chile","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"cristian","middleName":"osvaldo","lastName":"salas","suffix":""}],"badges":[],"createdAt":"2021-07-27 21:15:02","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-756093/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-756093/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":12119901,"identity":"585ea5b9-d666-415c-a562-3277dc8e5c05","added_by":"auto","created_at":"2021-08-04 20:51:31","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":28228,"visible":true,"origin":"","legend":"Chemical structures of lapachol (I), α-lapachone (II) and aryloxy-quinones (III-VI) with trypanosomicidal activity, and new aryloxy-naphthoquinones studied in this work","description":"","filename":"Fig01.png","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/2b3228f77f29f479a96711ed.png"},{"id":12119902,"identity":"85deb3e7-ea9a-458e-9eaa-f213ab5ab0b6","added_by":"auto","created_at":"2021-08-04 20:51:31","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":79896,"visible":true,"origin":"","legend":"Pharmacophores of molecules with high (a) or low (b) bioactivity and observed differences (c) between both models","description":"","filename":"Fig02.png","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/6026560fd79e4e9b552bfd50.png"},{"id":12119904,"identity":"e0c1ad81-4a39-4cf0-a5ee-396bc1c74d1e","added_by":"auto","created_at":"2021-08-04 20:51:31","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":111022,"visible":true,"origin":"","legend":"Pharmacophores of molecules with high (a) or low (b) bioactivity (NINOA T. cruzi epimastigotes) and observed differences (c) between both models","description":"","filename":"Fig03.png","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/8fd36c2f2aebecd479acdc15.png"},{"id":13707405,"identity":"584054e1-2135-45ce-93b0-627f0c6bd9b3","added_by":"auto","created_at":"2021-09-17 14:02:37","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":852229,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/64c2f73f-bc8f-4c69-86ed-7a60c64f3dcd.pdf"},{"id":12119905,"identity":"abcf6cff-6db0-458d-9623-56fe65799b53","added_by":"auto","created_at":"2021-08-04 20:51:31","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":1561836,"visible":true,"origin":"","legend":"","description":"","filename":"SupportinginformationMCR2021.docx","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/783040bceefe574c63287086.docx"},{"id":12119906,"identity":"ed96e0f2-bdf6-4e7f-bda1-3286df779560","added_by":"auto","created_at":"2021-08-04 20:51:31","extension":"png","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":320532,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/3da9d03d9d9ce9ff9cb1729f.png"},{"id":12119903,"identity":"92490786-e5ef-444c-b7d2-a4467f9fc03b","added_by":"auto","created_at":"2021-08-04 20:51:31","extension":"png","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":34773,"visible":true,"origin":"","legend":"Scheme 1 Synthesis of aryloxy-naphthoquinone derivatives. Reagents and conditions: a) K2CO3, DMF, rt, 2-3 h, 23-67%.","description":"","filename":"Scheme01.png","url":"https://assets-eu.researchsquare.com/files/rs-756093/v1/3c998c7a7985829d981be17d.png"}],"financialInterests":"","formattedTitle":"\u003cp\u003eExpanding the Chemical Space of Aryloxy-naphthoquinones as Potential Anti-chagasic Agents: Synthesis and Trypanosomicidal Activity\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eChagas disease or American trypanosomiasis is one of the 20 \u0026ldquo;Neglected Tropical Diseases\u0026rdquo; (NTD) (WHO, 2020). The disease is caused by \u003cem\u003eTrypanosoma cruzi\u003c/em\u003e (\u003cem\u003eT. cruzi\u003c/em\u003e), a protozoan parasite endemic in Latin America. It affects approximately 7\u0026nbsp;million people and causes more than 10 000 deaths a year [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. There are two drugs approved for the treatment of this disease, benznidazole (Bzn) and nifurtimox (Nfx) [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Both are effective in the early stages of the disease (acute stage), but their efficacy is limited in advanced stages (chronic stage). These drugs also present serious adverse effects and require long-term therapy leading to treatment suspension [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Considering the above and the fact the pharmaceutical industry does not invest in research for NTDs, it is great importance to find new alternatives for the treatment of trypanosomiasis. For this reason, many academic research groups are searching for new trypanosomicidal therapeutic alternatives through the design and synthesis of small molecules [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCompounds derived from a naphthoquinone scaffold appear to be an interesting alternative for the Chagas disease pharmacotherapy. Lapachol \u003cb\u003eI\u003c/b\u003e and α-lapachone \u003cb\u003eII\u003c/b\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) are important naphthoquinone derivatives in nature with trypanosomicidal activity [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Considering this background, a library of 2-aryloxy-1,4-naphthoquinone compounds were synthesized by Bolognesi et al. 2-phenoxy-1,4-naphthoquinone \u003cb\u003eIII\u003c/b\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) was the most prominent derivative in this series, with an IC\u003csub\u003e50\u003c/sub\u003e of 1.70 \u0026micro;M against \u003cem\u003eT. cruzi\u003c/em\u003e amastigotes [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn recent years, our research group has focused on the search for new anti-\u003cem\u003eT. cruzi\u003c/em\u003e agents containing the structure of the aryloxy-quinone scaffold. Our first approach was through the synthesis of aryloxy-indolequinone derivatives and their evaluation against \u003cem\u003eT. cruzi\u003c/em\u003e epimastigotes culture. Of these, 6-phenoxyindolequinone derivative \u003cb\u003eIV\u003c/b\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) showed excellent inhibitory activity in the nanomolar range against Y strain epimastigote (IC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;20 nM) [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn a subsequent article, our group reported the synthesis and trypanosomicidal activity of 2-aryloxy-naphthoquinones, 7-aryloxyquinolinquinones and 6-aryloxy-furonaphthoquinones derivatives [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. In this work compound 2-(3-nitrophenyloxy)-naphthoquinone \u003cb\u003eV\u003c/b\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) showed an IC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;20 nM and a selectivity index (SI) of 625 against J774 murine macrophage cells, which showed low toxicity against non-neoplastic cells. In our last report on aryloxy-naphthoquinones with trypanosomicidal activity, we obtained good results against epimastigote cultures with an IC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;230 nM for 2-(4-methyl-3-nitrophenoxy)-naphthoquinone \u003cb\u003eVI\u003c/b\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFrom these results, we observed the presence of an aryloxy group attached to the naphthoquinone core is important for anti-\u003cem\u003eT. cruzi\u003c/em\u003e activity. Furthermore, we have noticed the addition of a nitro or a methyl group on the aryloxy moiety gives rise to compounds with equal or better trypanosomicidal activity. It remarked that Nfx and Bzn, drugs have been used in the chemotherapy of Chagas disease, have a nitro group in their structure. Interestingly, in 2017 the FDA has approved Bzn as pharmacological treatment for the Chagas disease [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Therefore, considering the aforementioned, in this work, we carried out the synthesis of new naphthoquinones (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), which was functionalized according to four criteria, to evaluate the effect of these modifications on the trypanosomicidal effect on epimastigote and tripomastigote forms from Mexican strains of \u003cem\u003eT. cruzi\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eThese modifications were: (a) the substitution of the hydrogen atom on C-3 by bromine or chlorine because it has been reported that this change modulates the trypanosomicidal activity on Tulahu\u0026eacute;n, NINOA, INC-5 and Y strains [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. In the aryloxy moiety: (b) the substitutions of a nitro group in the aryloxy moiety at \u003cem\u003emeta\u003c/em\u003e or \u003cem\u003epara\u003c/em\u003e position; (c) as shown in \u003cb\u003eVI\u003c/b\u003e, a methyl group at \u003cem\u003epara\u003c/em\u003e position and \u003cem\u003emeta\u003c/em\u003e position; (d) a substitution at \u003cem\u003epara\u003c/em\u003e position by chlorine atom. With these new derivatives, our group expanded the library of compounds with trypanosomicidal activity and contributed to the chemical space of naphthoquinones with anti-Chagasic activity.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Experimental Section","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eGeneral\u003c/h2\u003e \u003cp\u003eMelting points were determined on a Kofler Thermogerate apparatus and were uncorrected. IR spectra were recorded on a JASCO FT/IR-400 spectrophotometer. NMR spectra were recorded, unless otherwise specified, on a Bruker AM-400 instrument using deuterochloroform (CDCl\u003csub\u003e3\u003c/sub\u003e) or deuterodimethylsulfoxide (DMSO-δ) solutions containing tetramethylsilane as an internal standard. Samples were analysed using an Advion (Itaca, NY, USA) Expression-L mass spectrometer equipped with an electrospray ionization source (ESI). Sample were directly injected (5 \u0026micro;L) using LC-grade methanol as mobile phase. Mass spectrometry analysis was carried out using the following settings: ESI (-) voltage of 2.5 kV, nebulizer gas (N\u003csub\u003e2\u003c/sub\u003e) flow: 3.0 L min-1, drying gas flow: 10 L min-1, desolvation line temperature 200\u0026deg;C and heat block temperature 250\u0026deg;C. Analytes were evaluated in Full Scan mode (m/z) 100\u0026ndash;1500. Data was acquired by means of Advion Mass Express and processed applying Data Express Software. Thin layer chromatography (TLC) was performed using Merck GF-254 type 60 silica gel. Column chromatography was carried out using Merck type 9385 silica gel. The purity of the compounds was determined by TLC. All the spectra of aryloxy-quinones synthesized are shown in the Supporting information.\u003c/p\u003e \u003cp\u003e \u003cb\u003eGeneral procedure for the synthesis of aryloxy-naphthoquinones.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eIn a reaction flask, the suitable phenol (1.1 mmol) and K\u003csub\u003e2\u003c/sub\u003eCO\u003csub\u003e3\u003c/sub\u003e (2 mmol) were suspended in DMF (5 mL). The mixture was stirred for 10 min, and then, the corresponding naphthoquinone (1 mmol) was added. Later, the reaction mixture was stirred for 2\u0026ndash;3 h at room temperature. The solvent was then removed under vacuum, and the solid residue was purified by column chromatography on silica gel and using dichloromethane as the mobile phase.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-(4-Methyl-3-nitrophenoxy)naphthalene-1,4-dione 3a.\u003c/b\u003e Yellow solid, yield 63 %, mp 163\u0026ndash;165\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 8.21\u0026ndash;8.15 (m, 1H), 8.10\u0026ndash;8.03 (m, 1H), 7.81 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2.5 Hz, 1H), 7.79\u0026ndash;7.75 (m, 2H), 7.46 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.4 Hz, 1H), 7.32 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.4, 2.5 Hz, 1H), 6.01 (s, 1H), 2.64 (s, 3H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, CDCl3) δ 184.48, 179.34, 159.48, 151.07, 149.73, 134.67, 134.63, 133.81, 131.99, 131.82, 130.96, 126.90, 126.38, 125.71, 117.51, 114.42, 20.12. MS (ESI) for (C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e11\u003c/sub\u003eNO\u003csub\u003e5\u003c/sub\u003e [M-]): 309.3. Found 309.0.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Chloro-3-(4-methyl-3-nitrophenoxy)naphthalene-1,4-dione 3b.\u003c/b\u003e Yellow solid, yield 23 %, mp 201\u0026ndash;203\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 8.22 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;7.0 Hz, 1H), 8.05 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;6.8 Hz, 1H), 7.85\u0026ndash;7.74 (m, 2H), 7.61 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;1.6 Hz, 1H), 7.33 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.4 Hz, 1H), 7.24\u0026ndash;7.17 (m, 1H), 2.58 (s, 3H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 178.02, 177.62, 154.49, 152.74, 149.27, 134.85, 134.67, 134.47, 134.00, 131.16, 130.43, 129.37, 127.58, 127.31, 121.66, 112.82, 20.02. MS (ESI) for (C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e10\u003c/sub\u003eClNO\u003csub\u003e5\u003c/sub\u003e [M-]): 343.0. Found 343.0.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Bromo-3-(4-methyl-3-nitrophenoxy)naphthalene-1,4-dione 3c.\u003c/b\u003e Yellow solid, yield 24 %, mp 188\u0026ndash;190\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, CDCl3) δ 8.16\u0026ndash;8.08 (m, 1H), 7.95 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;7.2, 1.7 Hz, 1H), 7.76\u0026ndash;7.64 (m, 2H), 7.52 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2.6 Hz, 1H), 7.24 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.5 Hz, 1H), 7.13 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.4, 2.6 Hz, 1H), 2.49 (s, 3H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 178.07, 177.09, 155.21, 154.37, 149.28, 134.81, 134.59, 134.01, 131.06, 130.44, 129.33, 128.61, 127.84, 127.37, 121.64, 112.81, 20.02. MS (ESI) for (C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e10\u003c/sub\u003eBrNO\u003csub\u003e5\u003c/sub\u003e [M-]): 386.9. Found 387.0\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-(4-Chloro-3-nitrophenoxy)naphthalene-1,4-dione 3d.\u003c/b\u003e Yellow solid, yield 54 %, mp 164\u0026ndash;165\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 8.18\u0026ndash;8.14 (m, 1H), 8.09\u0026ndash;8.05 (m, 1H), 7.83\u0026ndash;7.74 (m, 2H), 7.72 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2.8 Hz, 1H), 7.65 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.8 Hz, 1H), 7.35 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.8, 2.8 Hz, 1H), 6.11 (s, 1H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 184.25, 179.06, 158.73, 151.80, 148.51, 134.80, 133.97, 133.66, 131.75, 130.88, 126.95, 126.48, 125.68, 124.71, 118.27, 115.61. MS (ESI) for (C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e8\u003c/sub\u003eClNO\u003csub\u003e5\u003c/sub\u003e [M-]): 329.0. Found 328.9.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Chloro-3-(4-chloro-3-nitrophenoxy)naphthalene-1,4-dione 3e\u003c/b\u003e. Yellow solid, yield 43 %, mp 199\u0026ndash;201\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, DMSO) δ 8.14 (dd, J\u0026thinsp;=\u0026thinsp;7.3, 1.4 Hz, 1H), 8.09 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2.9 Hz, 1H), 8.02 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;7.1, 1.7 Hz, 1H), 7.99\u0026ndash;7.92 (m, 2H), 7.80 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.9 Hz, 1H), 7.67 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.9, 3.0 Hz, 1H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, DMSO) δ 178.47, 177.95, 155.51, 151.95, 148.86, 135.15, 135.01, 134.85, 133.13, 131.94, 131.10, 127.14, 127.00, 122.24, 119.30, 113.43. MS (ESI) for (C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e7\u003c/sub\u003eCl\u003csub\u003e2\u003c/sub\u003eNO\u003csub\u003e5\u003c/sub\u003e [M-]): 362.9. Found 363.0.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Bromo-3-(4-chloro-3-nitrophenoxy)naphthalene-1,4-dione 3f.\u003c/b\u003e Yellow solid, yield 67 %, mp 196\u0026ndash;198\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, DMSO) δ 8.18\u0026ndash;8.11 (m, 1H), 8.08 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2.9 Hz, 1H), 8.06\u0026ndash;7.98 (m, 1H), 7.97\u0026ndash;7.87 (m, 2H), 7.79 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.9 Hz, 1H), 7.66 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8.9, 2.9 Hz, 1H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, DMSO) δ 178.73, 177.47, 155.39, 154.40, 148.90, 135.08, 134.93, 133.11, 131.83, 131.13, 129.70, 127.38, 127.07, 122.19, 119.17, 113.37. MS (ESI) for (C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e7\u003c/sub\u003eBrClNO\u003csub\u003e5\u003c/sub\u003e [M-]): 408.6. Found 409.0.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Chloro-3-(4-nitrophenoxy)naphthalene-1,4-dione 3g.\u003c/b\u003e Yellow solid, yield 61 %, mp 169\u0026ndash;170\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 8.40\u0026ndash;8.31 (m, 3H), 8.21\u0026ndash;8.15 (m, 1H), 8.00\u0026ndash;7.86 (m, 2H), 7.28\u0026ndash;7.13 (m, 2H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, CDCl\u003csub\u003e3\u003c/sub\u003e) δ 177.86, 177.28, 160.65, 152.42, 143.89, 134.98, 134.81, 131.14, 130.33, 127.68, 127.38, 126.04, 116.77. MS (ESI) for (C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e8\u003c/sub\u003eClNO\u003csub\u003e5\u003c/sub\u003e [M-]): 329.0. Found 328.9.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Chloro-3-(3-methyl-4-nitrophenoxy)naphthalene-1,4-dione 3h.\u003c/b\u003e Yellow solid, yield 37 %, mp 170\u0026ndash;171\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, DMSO) δ 8.19\u0026ndash;8.10 (m, 1H), 8.06 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;9.0 Hz, 1H), 8.01 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;7.1, 1.5 Hz, 1H), 7.98\u0026ndash;7.87 (m, 2H), 7.38 (d, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;2.5 Hz, 1H), 7.31 (dd, \u003cem\u003eJ\u003c/em\u003e\u0026thinsp;=\u0026thinsp;9.0, 2.7 Hz, 1H), 2.51 (s, 2H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, DMSO) δ 178.48, 177.94, 159.47, 152.08, 144.56, 136.99, 135.16, 135.02, 134.99, 131.98, 131.06, 127.69, 127.18, 127.04, 119.70, 115.16, 20.46. MS (ESI) for (C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e10\u003c/sub\u003eClNO\u003csub\u003e5\u003c/sub\u003e [M-]): 343.0. Found 343.0.\u003c/p\u003e \u003cp\u003e \u003cb\u003e2-Bromo-3-(3-methyl-4-nitrophenoxy)naphthalene-1,4-dione 3i.\u003c/b\u003e Yellow solid, yield 32 %, mp 174\u0026ndash;176\u0026deg;C. \u003csup\u003e1\u003c/sup\u003eH NMR (400 MHz, CDCl3) δ 8.27\u0026ndash;8.11 (m, 1H), 8.11\u0026ndash;7.95 (m, 2H), 7.85\u0026ndash;7.71 (m, 2H), 6.94\u0026ndash;6.87 (m, 2H), 2.59 (s, 3H). \u003csup\u003e13\u003c/sup\u003eC NMR (101 MHz, CDCl3) δ 178.00, 176.87, 158.86, 154.99, 144.74, 137.29, 134.89, 134.69, 131.08, 130.38, 129.07, 127.92, 127.49, 127.46, 119.90, 114.41, 21.27. MS (ESI) for (C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e10\u003c/sub\u003eBrNO\u003csub\u003e5\u003c/sub\u003e [M-]): 386.9. Found 387.0.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eTrypanosomicidal effect\u003c/h2\u003e \u003cp\u003e \u003cem\u003eT. cruzi\u003c/em\u003e NINOA and INC-5 strain epimastigotes were grown at 28\u0026deg;C in an axenic medium (BHI), as previously described [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e], and complemented with 5 % foetal bovine serum. Epimastigotes from a 10-day-old culture (stationary phase) were inoculated into 50 mL of fresh culture medium to reach an initial concentration of 1 \u0026times; 10\u003csup\u003e6\u003c/sup\u003e. Cell growth was monitored by measuring culture absorbance of the culture at 600 nm in an ELISA Epoch reader (Epoch 2 Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) every day. Before inoculation, the media was supplemented with a given amount of the drug from a stock solution in DMSO (25 mM). The final DMSO concentration in the culture medium never exceeded 0.4 % and the control was run in the presence of 0.4 % DMSO and in the absence of drugs. The percentage of growth inhibition (% GI) and half-maximal inhibitory concentration values (IC\u003csub\u003e50\u003c/sub\u003e), and parasite growth were followed in the absence (control), and in the presence, of a range of concentrations of the corresponding drug. On day 5, the absorbance of the culture was measured and related to the control. The IC\u003csub\u003e50\u003c/sub\u003e value was determined as the concentration of drug needed to reduce the absorbance ratio by 50 %. The experiments of each compound were carried out in triplicate; Bzn was used as a reference compound.\u003c/p\u003e \u003cp\u003e \u003cspan type=\"BoldItalic\" class=\"BoldItalic\" name=\"Emphasis\"\u003eEx vivo\u003c/span\u003e \u003cb\u003eevaluation of INC-5 and NINOA strain trypomastigotes\u003c/b\u003e\u003c/p\u003e \u003cp\u003eCD1 mice, 6 to 8 weeks old, were peritoneally infected with bloodstream trypomastigotes of the INC-5 and NINOA strains, respectively. After 4 to 6 weeks, at the maximum peak of parasitaemia, the parasitized blood was obtained by cardiac puncture using sodium heparin as an anticoagulant. Blood was adjusted to 1 x 10\u003csup\u003e6\u003c/sup\u003e trypomastigotes/mL. In a 96-well plate, 90 \u0026micro;l of infected blood and 10 \u0026micro;l of 1,4-naphthoquinone derivatives or reference drug dilutions were deposited for a final volume of 100 \u0026micro;l per well. Each evaluation was carried out in triplicate. The compounds with the best IC\u003csub\u003e50\u003c/sub\u003e in the epimastigotes of each strain were evaluated in trypomastigotes of both strains at 20 \u0026micro;M, 10 \u0026micro;M and 5 \u0026micro;M. The reference drug benznidazole was used as a positive lysis control and wells with untreated blood trypomastigotes were used as a negative lysis control; the microplates were incubated at 4\u0026deg;C for 24 h. Subsequently, mobile trypomastigotes were quantified using the Brener-Pizzi method, for this, 5 \u0026micro;L of blood was deposited between a slide and a 13 \u0026times; 13 coverslip. The trypomastigotes were counted in 15 microscope fields in an optical microscope with 40x magnification. The percentage of lysis of each treatment was calculated by comparing the viable trypomastigotes with the negative control [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. The LC\u003csub\u003e50\u003c/sub\u003e was determined by linear regression. The experiments were carried out in accordance with the recommendations and approval of the local Ethics and Research Committee (Approval number: ENCB / CEI / 078/2020).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eCytotoxicity assays\u003c/h2\u003e \u003cp\u003eA 96-well plate was seeded with 50 000 cells/well with RPMI medium and 2 % foetal bovine serum and incubated for 24 h at 37\u0026deg;C. The compound from stock was dissolved in DMSO for subsequent serial dilutions with PBS until a concentration in the plate that did not exceed 1 % of DMSO was reached. After 24 h, the culture medium was removed from the plate and fresh culture medium was added together with the compounds reaching a final volume of 100 \u0026micro;l per well. The plate was then incubated for 24 h at 37\u0026deg;C in 5 % CO\u003csub\u003e2\u003c/sub\u003e where the following controls were added: cells with the medium as a positive control; cells without culture medium as a negative control; and last, the reference drug, Bzn at a concentration of 20 \u0026micro;M.\u003c/p\u003e \u003cp\u003eAfter 24 h of incubation, the cell morphology was observed with a microscope and the MTT viability assay was performed. The culture medium was removed and the MTT solution was prepared and later added to the cells; it was incubated for 1 h and the absorbance was read at 570 nm. The following formula was used to obtain the percentage: % cytotoxicity = (100-(mean number of cells with treatment/cells without treatment) *100) [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003ePharmacophore\u003c/h2\u003e \u003cp\u003eA flexible alignment strategy was used, consisting of the overlap of 3D structures, and minimizing the relative distances between equivalent atoms, including the flexibility for all freedom degrees for all rotatable dihedral bonds. Polar-Charged-Hydrophobic (PCH) of the MOE program was used and evaluated over a centroid position (an averaged position of all atoms relates to the feature). Pharmacophoric features in this scheme are annotated as Aro (aromatic), hydrophobic (Hyd), acceptor hydrogen bonding (Acc), and capacity to bound to metallic centres (ML). Afterward, databases were spotted in groups of high and low growth inhibition of parasites in epimastigotes or trypomastigotes of INC-5, NINOA, respectively. For each group, a pharmacophore was built, and all features present in a minimum of 60 % of molecules were retained. Finally, all pharmacophores were compared.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results And Discussion","content":"\u003cdiv class=\"Section2\" id=\"Sec3\"\u003e\n \u003ch2\u003eChemistry\u003c/h2\u003e\n \u003cp\u003eWe synthesized new aryloxy-naphthoquinones by nucleophilic substitution reaction of phenols with halo or dihaloquinones in a basic medium at room temperature (Scheme \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e) [\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e]. These aryloxy-naphthoquinones were obtained from low to moderate yields (23\u0026ndash;67%). The chemical structures of the compounds \u003cstrong\u003e3a-i\u003c/strong\u003e were established based on their spectral properties (IR, \u003csup\u003e1\u003c/sup\u003eH-NMR, \u003csup\u003e13\u003c/sup\u003eC-NMR and MS). The chemical structures and the yield for the synthesis of \u003cstrong\u003e3a-i\u003c/strong\u003e are shown in the Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e\n \u003cdiv class=\"gridtable\"\u003e\u0026nbsp;\u003ctable border=\"1\" id=\"Tab1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eYields for synthesis of aryloxy-naphthoquinone derivatives\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCompound\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eStructure\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eYield (%)\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3a\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098115.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e63\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3b\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098123.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3c\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098134.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3d\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098144.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e54\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098151.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3f\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098160.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3g\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098168.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e61\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3h\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098175.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e\u003cstrong\u003e3i\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e\u003cimg src=\"https://myfiles.space/user_files/69519_bce2c0439cd956a6/69519_custom_files/img1628098182.png\"\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cp\u003e\u003cstrong\u003eBiology\u003c/strong\u003e\u003c/p\u003e\n\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eTrypanosomicidal effect against on the epimastigote form\u003c/h2\u003e \u003cp\u003eFirst, a screening assay was performed on the INC-5 and NINOA strains at a fixed concentration of 10 \u0026micro;M to determine the trypanosomicidal effect against epimastigote cultures. The results indicated that all compounds had a percentage of growth inhibition (% GI) in both strains greater than 70%. Considering these results, a dose-dependent assay was carried out using different concentrations (5 \u0026micro;M, 2.5 \u0026micro;M, 1.25 \u0026micro;M, 0.625 \u0026micro;M to determine the half-maximal inhibitory concentration (IC\u003csub\u003e50\u003c/sub\u003e) in each strain (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eAll the naphthoquinone derivatives showed greater potency than the reference drug Bzn on the INC-5 and NINOA epimastigotes strains. Interestingly, compounds \u003cb\u003e3i\u003c/b\u003e and \u003cb\u003e3c\u003c/b\u003e were 1000 and 100-fold more potent than Bzn against the INC-5 strain, respectively. From the chemical point of view, the most active compounds in both strains were \u003cb\u003e3i\u003c/b\u003e (IC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;40 nM on INC-5) and \u003cb\u003e3f\u003c/b\u003e (IC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;1.14 \u0026micro;M on INC-5). These compounds present a bromine atom at 3-position on the naphthoquinone scaffold. In general, in the INC-5 strain, compounds that have a halogen at 3-position, had greater potency than those did not present a substitution in this position (\u003cb\u003e3a\u003c/b\u003e and \u003cb\u003e3d\u003c/b\u003e). The same observation was noticed in the NINOA strain except for compound \u003cb\u003e3d\u003c/b\u003e, which presented a potency comparable to the derivatives that have halogens at 3-position. On the other hand, the position of the nitro, chloro, or methyl group on the aryloxy moiety does not seem to significantly affect the activity in either strain. However, the halogen attached at 3-position on the naphthoquinone core seems to influence the potency over epimastigotes, since the molecules with a bromine atom were more potent than those with a chlorine atom, and those without substitution in this position are the least active. Therefore, the order of activity follows the pattern: Br\u0026thinsp;\u0026gt;\u0026thinsp;Cl\u0026thinsp;\u0026gt;\u0026thinsp;H.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eEffect of \u003cb\u003e3a-i\u003c/b\u003e and Bzn on culture growth of epimastigote and trypomastigote forms of \u003cem\u003eT. cruzi\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eCompound\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eEpimastigote form\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003eTrypomastigote form\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eINC-5 IC\u003c/b\u003e\u003csub\u003e\u003cb\u003e50\u003c/b\u003e\u003c/sub\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003e(\u0026micro;M)\u003c/b\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eNINOA IC\u003c/b\u003e\u003csub\u003e\u003cb\u003e50\u003c/b\u003e\u003c/sub\u003e \u003cb\u003e(\u0026micro;M)\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003eINC-5 LC\u003c/b\u003e\u003csub\u003e\u003cb\u003e50\u003c/b\u003e\u003c/sub\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003e(\u0026micro;M)\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003eNINOA LC\u003c/b\u003e\u003csub\u003e\u003cb\u003e50\u003c/b\u003e\u003c/sub\u003e \u003cb\u003e(\u0026micro;M)\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3a\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.73\u0026thinsp;\u0026plusmn;\u0026thinsp;0.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e4.86\u0026thinsp;\u0026plusmn;\u0026thinsp;0.07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNT\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3b\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.51\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.06\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9.38\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3c\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.41\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e1.70\u0026thinsp;\u0026plusmn;\u0026thinsp;0.42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e24.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e20.35\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3d\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e1.63\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e2.26\u0026thinsp;\u0026plusmn;\u0026thinsp;0.07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3e\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.66\u0026thinsp;\u0026plusmn;\u0026thinsp;0.01\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e2.15\u0026thinsp;\u0026plusmn;\u0026thinsp;0.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3f\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.88\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e1.14\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e24.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e20.01\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3g\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.64\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e1.41\u0026thinsp;\u0026plusmn;\u0026thinsp;0.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e39.11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9.75\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3h\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.67\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e1.45\u0026thinsp;\u0026plusmn;\u0026thinsp;0.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNT\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3i\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.04\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e1.84\u0026thinsp;\u0026plusmn;\u0026thinsp;0.18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e27.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e35.36\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBzn\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e42.3\u0026thinsp;\u0026plusmn;\u0026thinsp;5.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e8.21\u0026thinsp;\u0026plusmn;\u0026thinsp;1.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e46.67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e40.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003csup\u003ea\u003c/sup\u003eThe results are means of three independent experiments\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003csup\u003eb\u003c/sup\u003eNT = not tested\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eTrypanosomicidal effect against on the trypomastigote\u003c/h2\u003e \u003cp\u003eThe half-maximal lytic concentration (LC\u003csub\u003e50\u003c/sub\u003e) in the trypomastigote form of both strains was measured for the compounds showed the lowest IC\u003csub\u003e50\u003c/sub\u003e values. The best results were obtained in the NINOA strain with LC\u003csub\u003e50\u003c/sub\u003e values of 9.38 and 9.75 \u0026micro;M for compounds \u003cb\u003e3b\u003c/b\u003e and \u003cb\u003e3g\u003c/b\u003e, respectively (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). These compounds were four-fold more active than Bzn (LC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;40.67 \u0026micro;M). On the other hand, in the INC-5 strain, two compounds, \u003cb\u003e3c\u003c/b\u003e and \u003cb\u003e3g\u003c/b\u003e showed approximately two-fold greater potency than Bzn (LC\u003csub\u003e50\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;46.67 \u0026micro;M). However, it was not possible to establish a structure-activity relationship in trypomastigotes because the assayed compounds were limited in number It is remarkable that in NINOA, the most active compounds were those with a chlorine atom at 3-position on the naphthoquinone core.\u003c/p\u003e \u003cp\u003eThe important results are obtained from these strains. The trypomastigote is the infective flagellated form of the parasite in the blood. This form is responsible for the acute and chronic stages of Chagas disease in mammalian hosts [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Epimastigotes were used as a primary screening because their replication is extracellular, and they are easy to handle and maintain in the laboratory [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eCytotoxicity in murine macrophages\u003c/h2\u003e \u003cp\u003eThe cytotoxicity of the most promising compounds \u003cb\u003e3b\u003c/b\u003e, \u003cb\u003e3c\u003c/b\u003e, \u003cb\u003e3f\u003c/b\u003e, \u003cb\u003e3g\u003c/b\u003e and \u003cb\u003e3i\u003c/b\u003e was determined on the murine macrophage J774 cell line (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). In general, the five derivatives had greater selectivity for the epimastigote form of both strains, with \u003cb\u003e3i\u003c/b\u003e being the compound with the highest selectivity index (SI\u0026thinsp;=\u0026thinsp;320). Moreover, it is important to point out the high selectivity of compound \u003cb\u003e3b\u003c/b\u003e against the NINOA strain in trypomastigotes. The SI for \u003cb\u003e3b\u003c/b\u003e was comparable with Bzn but with a better LC\u003csub\u003e50\u003c/sub\u003e on this strain than this reference drug.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSelective index (SI) values calculated for the most promising compounds\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCompound\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJ774 IC\u003csub\u003e50\u003c/sub\u003e\u003c/p\u003e \u003cp\u003e(\u0026micro;M)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eINC-5(Epi) SI\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNINOA (Epi)\u003c/p\u003e \u003cp\u003eSI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eINC-5(Tryp)\u003c/p\u003e \u003cp\u003eSI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNINOA(Tryp) SI\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3b\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e117\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e229\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e38.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNT\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e12.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3c\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e5.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3f\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3g\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e8.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e1.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3i\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e320\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e6.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBzn\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e352\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e42.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e8.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e\u003csup\u003ea\u003c/sup\u003eThe results are means of three independent experiments\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e\u003csup\u003eb\u003c/sup\u003eSI value\u0026thinsp;=\u0026thinsp;IC\u003csub\u003e50\u003c/sub\u003e values on J774 cells / IC\u003csub\u003e50\u003c/sub\u003e or LC\u003csub\u003e50\u003c/sub\u003e \u003cem\u003eT. cruzi\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"6\"\u003e\u003csup\u003ec\u003c/sup\u003eNT = not tested\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePharmacophoric elucidation\u003c/h2\u003e \u003cp\u003eCompounds were aligned by a flexible alignment technique. This technique overlaps 3D structures minimizing the relative distances between equivalent atoms (in each molecule), including flexibility that allows all degrees of freedom in the rotatable angles, covering all possible dihedral angles. The pharmacophoric model was built using the Polar-Charged-Hydrophobic (PCH) scheme in the MOE program [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. The model was built with all features present in at least 60% of aligned molecules, resulting in the selection of the following features: Aromatic rings (Aro); Hydrophobic centre (Hyd); Hydrogen bond acceptor capacity (Acc); Metal ligation site (ML), and a combination of these. Some combinations could be defined (Acc\u0026amp;ML). Considering that there are more IC\u003csub\u003e50\u003c/sub\u003e values for the epimastigote form in both strains, a pharmacophoric model was carried out.\u003c/p\u003e \u003cp\u003e \u003cb\u003ePharmacophoric models for INC-5 epimastigote\u003c/b\u003e \u003cspan type=\"BoldItalic\" class=\"BoldItalic\" name=\"Emphasis\"\u003eT. cruzi\u003c/span\u003e \u003cb\u003egrowth inhibitors\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe molecules were classified according to their trypanosomicidal (INC-5 epimastigotes) high or low growth inhibition (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e); their differential features were also detected. The main difference observed between both groups was sites bound to metals (\u003cem\u003emeta\u003c/em\u003e-position, red spheres) non-favouring bioactivity. In this place, a nitro group at \u003cem\u003emeta\u003c/em\u003e-position on aryloxy moiety favoured the desired bioactivity. This change affected the electronic density of the aromatic ring sustaining this group because of the high electronegativity of nitrogen and oxygen atoms of the nitro substituent.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003ePharmacophoric models of NINOA epimastigotes\u003c/b\u003e \u003cspan type=\"BoldItalic\" class=\"BoldItalic\" name=\"Emphasis\"\u003eT. cruzi\u003c/span\u003e \u003cb\u003egrowth inhibitors\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe molecules were classified according to their trypanosomicidal (NINOA epimastigotes) high or low growth inhibition (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e); their differential features were also detected. In this case, bioactivity (NINOA \u003cem\u003eT. cruzi\u003c/em\u003e epimastigotes growth inhibition) is favoured with the presence of acceptor groups of metallic atoms at \u003cem\u003epara\u003c/em\u003e position on the phenoxy group (cyan spheres) and non-favoured when these features are placed at \u003cem\u003emeta\u003c/em\u003e-position (red spheres).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003ePhysicochemical properties\u003c/h2\u003e \u003cp\u003eDrug-likeness properties such as the pharmacokinetic (ADME) and pharmacodynamic (e.g., toxicological) profiles are important during the process of discovery and development process of a drug. These properties are shown the optimization of a leading compound to a successful candidate for pre-clinical stages [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eADMET properties are important to determine some chemical descriptors such as the polar surface area (PSA) and the molecular weight (MW) of molecules, which are useful to determine the oral absorption of drugs. Small and hydrophilic molecules are undergoing rapid renal clearance, while large and hydrophobic compounds are undergoing extensive hepatic metabolism and poor absorption [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Therefore, finding a suitable hydrophilic-hydrophobic drug balance is a great challenge for medicinal chemists. Thus, to evaluate these properties and predict good oral bioavailability, two sets of rules, Lipinski and Veber, should be followed to make a good prediction [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eLipinski\u0026rsquo;s rule of five states that an orally bioavailable molecule should not violate the following criteria: \u0026le; 5 hydrogen bond donors (HBD); \u0026le; 10 hydrogen bond acceptors (HBA); a MW\u0026thinsp;\u0026lt;\u0026thinsp;500, and a log P-value\u0026thinsp;\u0026lt;\u0026thinsp;5. On the other hand, Veber et al. described the role of PSA and the number of rotatable bonds as criteria to estimate oral bioavailability. Veber\u0026rsquo;s rule states that the compound to be orally bioavailable, it should have either a PSA\u0026thinsp;\u0026le;\u0026thinsp;140 \u0026Aring; and \u0026le;\u0026thinsp;10 rotatable bonds (NRB) or \u0026le;\u0026thinsp;12 HBD and HBA in total and \u0026le;\u0026thinsp;10 rotatable bonds. As shown in Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e, compounds \u003cb\u003e3a-i\u003c/b\u003e achieved the Drug-likeness criteria described by Lipinski and Veber; therefore, they are expected to have good oral bioavailability.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMolecular properties of compounds \u003cb\u003e3a-i\u003c/b\u003e\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCompound\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMW (Da)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHBA\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHBD\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMiLogP\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTPSA (A\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNRB\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDesirable value\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;500\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;140\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;10\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3a\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e309.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3b\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e343.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3c\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e388.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3d\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e329.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3e\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e364.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3f\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e408.59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3g\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e329.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3h\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e343.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3i\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e388.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"7\"\u003eMW: Molecular weight; HBA: Number of hydrogen bond acceptors; HBD: Number of hydrogen bond donors; MiLogP: Log P value predicted by Molinspiration (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e\u003ca href=\"http://www.https://www.molinspiration.com\" target=\"_blank\"\u003ewww.https://www.molinspiration.com\u003c/a\u003e\u003c/span\u003e\u003c/span\u003e); TPSA: Topological polar surface; NRB: number of rotatable bonds.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn this study, a set of nine aryloxy-naphthoquinones were synthesised and evaluated \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003eex vivo\u003c/em\u003e against the epimastigote and trypomastigote forms in two Mexican \u003cem\u003eT. cruzi\u003c/em\u003e strains. The trypanosomicidal activity of these compounds against both forms and were better than the reference drug, benznidazole (Bzn). The most promising naphthoquinone derivative is compound \u003cb\u003e3b\u003c/b\u003e due to its highest trypanosomicidal activity against epimastigotes (INC-5 and NINOA strains) and trypomastigote (NINOA strain) and SI values. From the theoretical studies, important features from pharmacophoric models were identified to develop the more active naphthoquinone derivatives. Predictions about their ADME properties indicated that these aryloxy-naphthoquinones would have good bioavailability.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eC.O.S. thanks to DIPOG project N\u0026ordm; 3913-406-81 and C. E.-B. gratefully acknowledges the financial support from FONDECYT (Research Grant No. 1180292).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that there is no conflict of interest.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eOrganization WH. Available online: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/neglected_diseases/diseases/en/\u003c/span\u003e\u003c/span\u003e. 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZuma AA, de Souza W (2021) Chagas Disease Chemotherapy: What Do We Know So Far? Curr Pharm Des. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/1381612827666210216152654\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAltcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H (2011) Adverse Events After the Use of Benznidazole in Infants and Children With Chagas Disease. Pediatrics 127(1):e212\u0026ndash;e218. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1542/peds.2010-1172\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eApt BW, Heitmann GI, Jercic LM, Jotre ML, Munoz CDVP, Noemi HI et al (2008) [Guidelines for chagas disease: Part IV. Chagas disease in immune compromised patients]. Rev Chilena Infectol 25(4):289\u0026ndash;292. doi:/S0716-10182008000400008\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eScarim CB, Chin CM (2019) Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances. Comb Chem High Throughput Screen 22(8):509\u0026ndash;520. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/1386207322666191010144111\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVillalta F, Rachakonda G (2019) Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin Drug Discov 14(11):1161\u0026ndash;1174. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/17460441.2019.1652593\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoveris A, Docampo R, Turrens JF, Stoppani AO (1978) Effect of beta-lapachone on superoxide anion and hydrogen peroxide production in \u003cem\u003eTrypanosoma cruzi\u003c/em\u003e. Bioch J 175(2):431\u0026ndash;439. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1042/bj1750431\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDiogo EBT, Dias GG, Rodrigues BL, Guimar\u0026atilde;es TT, Valen\u0026ccedil;a WO, Camara CA et al (2013) Synthesis and anti-\u003cem\u003eTrypanosoma cruzi\u003c/em\u003e activity of naphthoquinone-containing triazoles: electrochemical studies on the effects of the quinoidal moiety. Bioorg Med Chem 21(21):6337\u0026ndash;6348. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bmc.2013.08.055\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBolognesi ML, Lizzi F, Perozzo R, Brun R, Cavalli A (2008) Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity. Bioorg Med Chem Lett 18(7):2272\u0026ndash;2276. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bmcl.2008.03.009\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTapia RA, Salas CO, V\u0026aacute;zquez K, Espinosa-Bustos C, Soto-Delgado J, Varela J et al (2014) Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents. Bioorg Med Chem Lett 24(16):3919\u0026ndash;3922. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.bmcl.2014.06.044\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eV\u0026aacute;zquez K, Espinosa-Bustos C, Soto-Delgado J, Tapia RA, Varela J, Birriel E et al (2015) New aryloxy-quinone derivatives as potential anti-Chagasic agents: synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis. RSC Adv 5(80):65153\u0026ndash;65166. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1039/C5RA10122K\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEspinosa-Bustos C, V\u0026aacute;zquez K, Varela J, Cerecetto H, Paulino M, Segura R et al (2020) New aryloxy-quinone derivatives with promising activity on \u003cem\u003eTrypanosoma cruzi\u003c/em\u003e. Arch Pharm 353(1):1900213. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/ardp.201900213\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJarvis LM (2018) the year in new drugs: fda approvals hit a 20-year high in 2017, with cancer and rare-disease drugs dominating the list of new medicines. Chem Eng News 96(4):25\u0026ndash;30\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGonz\u0026aacute;lez A, Becerra N, Kashif M, Gonz\u0026aacute;lez M, Cerecetto H, Aguilera E et al. \u003cem\u003eIn vitro\u003c/em\u003e and \u003cem\u003ein silico\u003c/em\u003e evaluations of new aryloxy-1,4-naphthoquinones as anti-\u003cem\u003eTrypanosoma cruzi\u003c/em\u003e agents. Med Chem Res. 2020;29(4):665 \u0026ndash; 74. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00044-020-02512-9\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTapia RA, Salas C, Morello A, Maya JD, Toro-Labbe A (2004) Synthesis of dihydronaphthofurandiones and dihydrofuroquinolinediones with trypanocidal activity and analysis of their stereoelectronic properties. Bioorg Med Chem 12(9):2451\u0026ndash;2458. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bmc.2004.01.046\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChac\u0026oacute;n-Vargas KF, Nogueda-Torres B, S\u0026aacute;nchez-Torres LE, Suarez-Contreras E, Villalobos-Rocha JC, Torres-Martinez Y et al. Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors. Molecules. 2017;22(2). doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules22020220\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMartin-Escolano R, Martin-Escolano J, Ballesteros-Garrido R, Cirauqui N, Abarca B, Rosales MJ et al (2020) Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-\u003cem\u003ea\u003c/em\u003e]pyridinium salts for Chagas disease treatment: \u003cem\u003eTrypanosoma cruzi\u003c/em\u003e cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition. Parasitol Res 119(9):2943\u0026ndash;2954. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00436-020-06779-0\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMOE (2013) Molecular Operating Environment 08, Chemical Computing. Group, Inc., Montreal\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeanwell NA (2011) Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 24(9):1420\u0026ndash;1456. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/tx200211v\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1\u0026ndash;3):3\u0026ndash;26. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0169-409x(00)00129-0\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVeber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615\u0026ndash;2623. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/jm020017n\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlvarez G, Varela J, Marquez P, Gabay M, Arias Rivas CE, Cuchilla K et al (2014) Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with \u003cem\u003ein vivo\u003c/em\u003e activity. J Med Chem 57(10):3984\u0026ndash;3999. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/jm500018m\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFaundez M, Pino L, Letelier P, Ortiz C, Lopez R, Seguel C et al (2005) Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to \u003cem\u003eTrypanosoma cruzi\u003c/em\u003e. Antimicrob Agents Chemother 49(1):126\u0026ndash;130. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1128/AAC.49.1.126-130.2005\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"medicinal-chemistry-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"mcre","sideBox":"Learn more about [Medicinal Chemistry Research](https://www.springer.com/journal/44)","snPcode":"44","submissionUrl":"https://submission.nature.com/new-submission/44/3","title":"Medicinal Chemistry Research","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Trypanosoma cruzi, trypomastigote, epimastigote, aryloxy-naphthoquinones, pharmacophoric analysis, ADME properties","lastPublishedDoi":"10.21203/rs.3.rs-756093/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-756093/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eIn continuation our effort to research the chemical space of aryloxy-naphthoquinones as potential anti-Chagas agents, we synthesized nine derivatives and these compounds were evaluated \u003cem\u003ein vitro\u003c/em\u003e against the epimastigote and trypomastigote forms of Mexican strains of \u003cem\u003eTrypanosoma cruzi\u003c/em\u003e (\u003cem\u003eT. cruzi\u003c/em\u003e). Most of these derivatives are highly active against epimastigote forms (IC\u003csub\u003e50\u003c/sub\u003e \u0026lt; 1.0 µM) compared to the reference drug benznidazole (Bzn). Then these were evaluated on trypomastigotes, which is showing better potency results than Bzn for compounds \u003cstrong\u003e3b\u003c/strong\u003e and \u003cstrong\u003e3g\u003c/strong\u003e. In addition, the cytotoxicity of these compounds was determined on the murine macrophage cell line J774. \u003cstrong\u003e3b\u003c/strong\u003e and \u003cstrong\u003e3i\u003c/strong\u003e were the most selective compounds against NINOA trypomastigote and INC-5 epimastigote forms, respectively. Further these compounds also have good oral bioavailability according to theoretical predictions. Finally, we were able to determine optimal substitution patterns using pharmacophoric models. All these results are provided very useful structural information to continue our designing of naphthoquinone derivatives against \u003cem\u003eT. cruzi\u003c/em\u003e.\u003c/p\u003e","manuscriptTitle":"Expanding the Chemical Space of Aryloxy-naphthoquinones as Potential Anti-chagasic Agents: Synthesis and Trypanosomicidal Activity","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-08-04 20:51:29","doi":"10.21203/rs.3.rs-756093/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major Revision","date":"2021-09-06T18:25:13+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2021-08-01T22:43:18+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2021-08-01T14:50:33+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2021-07-29T02:28:45+00:00","index":"","fulltext":""},{"type":"submitted","content":"Medicinal Chemistry Research","date":"2021-07-26T14:50:12+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"medicinal-chemistry-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"mcre","sideBox":"Learn more about [Medicinal Chemistry Research](https://www.springer.com/journal/44)","snPcode":"44","submissionUrl":"https://submission.nature.com/new-submission/44/3","title":"Medicinal Chemistry Research","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"9178fceb-a259-4b00-bd3c-848e9fb951c3","owner":[],"postedDate":"August 4th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":6223128,"name":"Medicinal Chemistry"}],"tags":[],"updatedAt":"2021-10-08T15:55:44+00:00","versionOfRecord":[],"versionCreatedAt":"2021-08-04 20:51:29","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-756093","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-756093","identity":"rs-756093","version":["v1"]},"buildId":"rHA-KDH7Qsr4HCuvH75dn","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}